The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: A Sarah Cannon Research Institute phase II trial.
J. A. Reeves
No relevant relationships to disclose
D. R. Spigel
No relevant relationships to disclose
D. B. Daniel
No relevant relationships to disclose
E. K. Friedman
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. D. Hainsworth
No relevant relationships to disclose